secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046067
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences reports Q4 net loss of $44.1M, cash $168.1M; pipeline trials on track
--------------------------------------------------------------------------------

- Cash and equivalents $168.1M at Dec 31, 2024; expected to fund operations into 2026.
- Q4 2024 net loss $44.1M ($0.84/sh) vs $59.5M ($1.13/sh) in Q4 2023; R&D expenses $31.8M.
- Tarcocimab Phase 3 GLOW2 (diabetic retinopathy) enrollment complete; topline data targeted 1Q2026.
- Tarcocimab & KSI-501 Phase 3 DAYBREAK (wet AMD) enrollment complete; topline data targeted 2Q2026.
- KSI-101 granted FDA Orphan Drug Designation; pivotal study initiation expected 2Q2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017025046067/0000950170-25-046067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017025046067/kod-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer